Skip to main content

BioVaxys acquires TAETSoftware to utilize Trial Adverse Events Tracker platform

BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to discuss the company's acquisition of TAETSoftware, a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (TAET) technology platform.

Passin says the acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting its core business in cancer and viral vaccine development.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.